From GlobeNewswire: 2024-08-05 08:00:00

Mesa Laboratories, Inc. reported strong first quarter fiscal year 2025 results, with revenues increasing by 14.9%. Non-GAAP core organic revenues grew by 3.0% and operating income by 940%. Key areas of focus include Sterilization and Disinfection Control, Clinical Genomics, Biopharmaceutical Development, and Calibration Solutions divisions. The company also improved its non-GAAP adjusted operating income metrics and reduced debt levels.

CEO Gary Owens highlighted a successful start to the fiscal year, with improvements in sales, marketing, profitability, and debt reduction. Revenues increased by 14.9%, driven by growth in core organic revenue and contributions from the GKE acquisition. Mesa Laboratories plans to decrease its total Net Leverage Ratio to below 3.0x in the future.

Division performance showed growth in Sterilization and Disinfection Control, Calibration Solutions, and Biopharmaceutical Development, with revenue increases ranging from 2.5% to 23.5%. Clinical Genomics faced challenges in China and North America, resulting in a revenue decline of 14.3%. Mesa Laboratories continues to focus on improving productivity and increasing profitability across all divisions.

The company’s financial results for the first quarter showed total revenues of $58,170, with operating income increasing 940% to $5,580. Net income also saw a significant increase of 717% to $3,388. Mesa Laboratories remains committed to delivering differentiated products and leveraging its strategic initiatives to outperform in the market.



Read more at GlobeNewswire:: Mesa Labs Announces First Quarter Results